These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22701561)

  • 1. New insights into the role of MHC diversity in devil facial tumour disease.
    Lane A; Cheng Y; Wright B; Hamede R; Levan L; Jones M; Ujvari B; Belov K
    PLoS One; 2012; 7(6):e36955. PubMed ID: 22701561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC gene copy number variation in Tasmanian devils: implications for the spread of a contagious cancer.
    Siddle HV; Marzec J; Cheng Y; Jones M; Belov K
    Proc Biol Sci; 2010 Jul; 277(1690):2001-6. PubMed ID: 20219742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low major histocompatibility complex diversity in the Tasmanian devil predates European settlement and may explain susceptibility to disease epidemics.
    Morris K; Austin JJ; Belov K
    Biol Lett; 2013 Feb; 9(1):20120900. PubMed ID: 23221872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-presenting genes and genomic copy number variations in the Tasmanian devil MHC.
    Cheng Y; Stuart A; Morris K; Taylor R; Siddle H; Deakin J; Jones M; Amemiya CT; Belov K
    BMC Genomics; 2012 Mar; 13():87. PubMed ID: 22404855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons learnt from the Tasmanian devil facial tumour regarding immune function in cancer.
    Peel E; Belov K
    Mamm Genome; 2018 Dec; 29(11-12):731-738. PubMed ID: 30225648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the Nonclassical MHC Class I, Saha-UD in the Transmissible Cancer Devil Facial Tumour Disease (DFTD).
    Hussey K; Caldwell A; Kreiss A; Skjødt K; Gastaldello A; Pye R; Hamede R; Woods GM; Siddle HV
    Pathogens; 2022 Mar; 11(3):. PubMed ID: 35335675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced effect of Tasmanian devil facial tumor disease at the disease front.
    Hamede R; Lachish S; Belov K; Woods G; Kreiss A; Pearse AM; Lazenby B; Jones M; McCallum H
    Conserv Biol; 2012 Feb; 26(1):124-34. PubMed ID: 21978020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allorecognition in the Tasmanian devil (Sarcophilus harrisii), an endangered marsupial species with limited genetic diversity.
    Kreiss A; Cheng Y; Kimble F; Wells B; Donovan S; Belov K; Woods GM
    PLoS One; 2011; 6(7):e22402. PubMed ID: 21811598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release.
    Pye R; Patchett A; McLennan E; Thomson R; Carver S; Fox S; Pemberton D; Kreiss A; Baz Morelli A; Silva A; Pearse MJ; Corcoran LM; Belov K; Hogg CJ; Woods GM; Lyons AB
    Front Immunol; 2018; 9():259. PubMed ID: 29515577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biting injuries and transmission of Tasmanian devil facial tumour disease.
    Hamede RK; McCallum H; Jones M
    J Anim Ecol; 2013 Jan; 82(1):182-90. PubMed ID: 22943286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils.
    Pye R; Hamede R; Siddle HV; Caldwell A; Knowles GW; Swift K; Kreiss A; Jones ME; Lyons AB; Woods GM
    Biol Lett; 2016 Oct; 12(10):. PubMed ID: 28120799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of non-classical MHC class I genes in the Tasmanian devil (Sarcophilus harrisii).
    Cheng Y; Belov K
    Immunogenetics; 2014 Dec; 66(12):727-35. PubMed ID: 25267059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a SNP-based assay for measuring genetic diversity in the Tasmanian devil insurance population.
    Wright B; Morris K; Grueber CE; Willet CE; Gooley R; Hogg CJ; O'Meally D; Hamede R; Jones M; Wade C; Belov K
    BMC Genomics; 2015 Oct; 16():791. PubMed ID: 26467759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils.
    Tovar C; Pye RJ; Kreiss A; Cheng Y; Brown GK; Darby J; Malley RC; Siddle HV; Skjødt K; Kaufman J; Silva A; Baz Morelli A; Papenfuss AT; Corcoran LM; Murphy JM; Pearse MJ; Belov K; Lyons AB; Woods GM
    Sci Rep; 2017 Mar; 7():43827. PubMed ID: 28276463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis and molecular biology of a transmissible tumor in the Tasmanian devil.
    Bender HS; Marshall Graves JA; Deakin JE
    Annu Rev Anim Biosci; 2014 Feb; 2():165-87. PubMed ID: 25384139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunology of a Transmissible Cancer Spreading among Tasmanian Devils.
    Woods GM; Howson LJ; Brown GK; Tovar C; Kreiss A; Corcoran LM; Lyons AB
    J Immunol; 2015 Jul; 195(1):23-9. PubMed ID: 26092814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematologic and serum biochemical changes associated with Devil Facial Tumor Disease in Tasmanian Devils.
    Peck S; Corkrey R; Hamede R; Jones M; Canfield P
    Vet Clin Pathol; 2016 Sep; 45(3):417-29. PubMed ID: 27589840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of MHC genes in contagious cancer: the story of Tasmanian devils.
    Caldwell A; Siddle HV
    Immunogenetics; 2017 Aug; 69(8-9):537-545. PubMed ID: 28695294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Devil Facial Tumours: Towards a Vaccine.
    Owen RS; Siddle HV
    Immunol Invest; 2019 Oct; 48(7):719-736. PubMed ID: 31161832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that disease-induced population decline changes genetic structure and alters dispersal patterns in the Tasmanian devil.
    Lachish S; Miller KJ; Storfer A; Goldizen AW; Jones ME
    Heredity (Edinb); 2011 Jan; 106(1):172-82. PubMed ID: 20216571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.